Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07128615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07128615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 4, 2025
Completion date
December 29, 2026
Enrollment
405 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a